Factual Summary
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a pharmaceutical company headquartered in Rahway, New Jersey, with an oncology, vaccine, and cardiovascular portfolio built around its core immuno-oncology product Keytruda (pembrolizumab). Second-quarter 2026 revenue was $25.310 billion (+6.6% year over year), with Non-GAAP adjusted EPS of $2.90 (+4.7% year over year).
Price-Change Context Note
No Merck-specific disclosure event was identified from primary sources on the decline date of 2026-07-20; what was confirmed was a downward revision of consensus earnings estimates and a rating change from a small research firm, both largely secondary-source in nature (ahead of the quarterly earnings release scheduled for 2026-08-04). Trading volume that day (7,729,047 shares) was below the recent average volume (approximately 9.90-10.36 million shares).
Business Overview & Recent Pipeline
- 2026-07-16: FDA approval of LIPFENDRA (enlicitide), an oral once-daily PCSK9 inhibitor — the CORALreef Lipids trial showed a 56% reduction in LDL-C at 24 weeks versus placebo.
- 2026-07-15: KEYTRUDA Phase 3 trial (KEYNOTE-C93) met its primary progression-free survival endpoint in advanced/recurrent mismatch repair-deficient (MMR-deficient) endometrial cancer.
- 2026-07-10: FDA approved an expanded indication for KEYTRUDA and KEYTRUDA QLEX in combination with PADCEV for perioperative treatment of muscle-invasive bladder cancer.
- 2026-03-25: Announced the acquisition of Terns Pharmaceuticals ($53 per share in cash, total equity value of approximately $6.7 billion).
Not available: segment-level revenue breakdown (pharmaceuticals/animal health) and certain fiscal year 2026 figures (excluded from this report due to conflicting figures across research sources).
5-Year Financial Trend
Revenue rose steadily from $48.704 billion in 2021 to $65.011 billion in 2025 (a CAGR of approximately 7.5%). Net income in 2023 fell sharply to $0.365 billion due to a surge in R&D expense, then recovered to $17.117 billion and $18.254 billion in 2024-2025 as R&D expense normalized from $17.938 billion to $15.789 billion.
Peer Comparison
| Company | P/E (Trailing) | P/E (Forward) | EV/EBITDA | Market Cap |
|---|---|---|---|---|
| Merck (MRK) | 34.79 | 20.31 | 11.88 | $307.25B |
| Pfizer (PFE) | 18.89 | 8.71 | 7.57 | $141.06B |
| Bristol-Myers Squibb (BMY) | 16.84 | 9.82 | 8.35 | $122.85B |
| Eli Lilly (LLY) | 40.74 | 31.83 | 29.28 | $1.02T |
| Johnson & Johnson (JNJ) | 28.84 | 20.53 | 18.14 | $598.96B |
As of 2026-07-21 (stockanalysis.com, A). Merck trades at a premium to industry peers on a trailing P/E basis, but its Forward P/E (20.31x) is closer to JNJ's (20.53x).
Valuation (Factual Multiples)
A P/B of 6.70x is high relative to book equity; this reflects an industry characteristic of pharmaceuticals in which intangible assets such as patents and pipeline value are not fully captured on the balance sheet.
Supply and Demand Trends
Trading volume on 2026-07-20 (7,729,047 shares) was below the recent average volume (approximately 9.90-10.36 million shares). Short interest as a share of float rose 3.68% versus the prior settlement date. Over the trailing 12 months, aggregate institutional buy transactions (2,576 transactions, $31.19B) exceeded sell transactions (2,121 transactions, $18.16B) in count and value, though this quarterly-disclosure-based data lags day-to-day flow. Insider (Form 4) filings over the past six months were predominantly stock option exercises, tax withholding, and annual compensation-related acquisitions; no open-market stock dispositions by insiders were identified.
Corporate Governance
The board combines the Chair and CEO roles (Robert M. Davis), but maintains an independent lead director (Thomas H. Glocer) and staffs all four standing committees entirely with independent directors. At the 2026-05-26 annual meeting, all 13 directors were re-elected (with approval rates of roughly 88-99.7%). BlackRock's 8.0% stake is from the most recent SC 13G/A filed on EDGAR (2024-01-26); Vanguard's prior 9.66% stake (as of 2024-02-13) has no confirmed subsequent update, so its current ownership percentage is not available.
Macro Environment
| Factor | Current Value | Reference Date |
|---|---|---|
| US Federal Funds Rate | 3.50-3.75% | 2026-06-17 FOMC (A) |
| US 10-Year Treasury Yield | 4.57% | 2026-07-20 (A) |
| US Dollar Index (DXY) | 100.7-100.8 | 2026-07-20 (A) |
| Healthcare Sector (XLV) | 161.09 | 2026-07-19 (A) |
Merck derives roughly 44% of revenue from outside the US (based on the first nine months of 2025), giving it significant currency exposure — a weaker dollar is factually positive for the dollar-translated value of revenue and earnings. Under Medicare drug price negotiation (IRA), Januvia's 2026 30-day supply price has been cut 79%, from $527 to $113, and Keytruda is scheduled to enter negotiation starting in 2028. Under the tariffs on branded pharmaceuticals stemming from the 2026-04-02 executive order, Merck secured an exemption through 2029-01-20 via an MFN and onshoring agreement.
Risk Factors (Factual)
- Keytruda accounted for approximately 46% of total company revenue in 2024 and is the company's core product; its active-ingredient patent is scheduled to expire around 2028-2029.
- Keytruda has been selected for 2026 Medicare drug price negotiation, with the new price scheduled to take effect from January 2028.
- 2025 Gardasil revenue declined approximately 39% year over year due to a shipment halt tied to excess distributor inventory at Chinese partner Zhifei.
- Tariffs on branded pharmaceuticals (up to 100%) stemming from the 2026-04-02 executive order were exempted for Merck through 2029-01-20 via an MFN and onshoring agreement signed 2025-12-19, in exchange for a committed $70 billion in US manufacturing investment.
- In fiscal year 2023, a surge in R&D expense from $13.548 billion to $30.531 billion in the prior year drove operating income down sharply from $17.945 billion to $2.355 billion.
- On 2026-07-01/02, Phase 2 trials of an Alzheimer's treatment (MK-1167) co-developed with partner Neuphoria Therapeutics were terminated early for lack of efficacy.
Theme Relevance
Fact Highlights
This is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.
Generated by FomoLog Agent · Data sources: KRX · NASDAQ · DART · SEC EDGAR